Metabolomics as a biomarker technology in pharmaceutical R&D

Virtual event

Participation is free of charge, but registration is required.

By entering your contact details, you agree to our Privacy policy.

Principal Clinical Biomarker Lead, Cardiometabolism, Boehringer Ingelheim, Germany

Assistant Professor of Research in Physiology and Biophysics, Weill Cornell Medicine, Qatar

Director | Business development
biocrates life sciences ag

Why better means of patient stratification are needed
Why metabolomics is a promising technology for biomarker research in pharmaceutical R&D
How metabolomics could help identify and overcome resistance mechanisms

4:00 pm (10:00 am EST)
Introduction: Why and how does metabolomics contribute to better therapies?
Stefan Ledinger, MA BSc

4:10 pm (10:10 am EST)
Multi-omics approaches for biomarker development in the pharmaceutical industry
Isabella Gashaw, PhD

4:40 pm (10:40 am EST)
Advancing cancer treatment by targeting dysregulated metabolism – A roadmap
Anna Maria Halama, PhD PhD

5:10 pm (11:10 am EST)
Wrap up
Stefan Ledinger, MA BSc